Homocysteine and methionine metabolism in renal failure.

Coen van Guldener, Coen D A Stehouwer
{"title":"Homocysteine and methionine metabolism in renal failure.","authors":"Coen van Guldener,&nbsp;Coen D A Stehouwer","doi":"10.1055/s-2005-872405","DOIUrl":null,"url":null,"abstract":"<p><p>Renal insufficiency is invariably accompanied by elevated plasma concentrations of the sulfur-containing and potentially vasculotoxic amino acid homocysteine. There is a strong relationship between glomerular filtration rate and plasma homocysteine concentration. Unlike creatinine, however, homocysteine is avidly reabsorbed in the renal tubules, and its urinary excretion is minimal. There is no evidence that homocysteine is actively removed by the human kidney. In renal insufficiency, plasma concentrations of S-adenosylmethionine, S-adenosylhomocysteine, cystathionine, cysteine, and sulfate are elevated, pointing to a remethylation or distal transsulfuration/oxidation block as the cause of hyperhomocysteinemia in renal failure. Stable isotope techniques have shown that both whole-body homocysteine remethylation and methionine transmethylation are decreased in renal failure, whereas homocysteine transsulfuration seems intact. Metabolic homocysteine clearance (i.e., transsulfuration relative to plasma homocysteine) is decreased to a major extent. These metabolic disturbances in renal failure can only be partially restored with current treatments. Folic acid treatment lowers plasma homocysteine concentration and increases remethylation and transmethylation rates. Plasma homocysteine, however, is not normalized, and metabolic homocysteine clearance by transsulfuration remains impaired. According to the currently available data, effective normalization of plasma homocysteine can only be obtained when its metabolic clearance through transsulfuration is restored.</p>","PeriodicalId":87139,"journal":{"name":"Seminars in vascular medicine","volume":"5 2","pages":"201-8"},"PeriodicalIF":0.0000,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2005-872405","citationCount":"36","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in vascular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-2005-872405","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 36

Abstract

Renal insufficiency is invariably accompanied by elevated plasma concentrations of the sulfur-containing and potentially vasculotoxic amino acid homocysteine. There is a strong relationship between glomerular filtration rate and plasma homocysteine concentration. Unlike creatinine, however, homocysteine is avidly reabsorbed in the renal tubules, and its urinary excretion is minimal. There is no evidence that homocysteine is actively removed by the human kidney. In renal insufficiency, plasma concentrations of S-adenosylmethionine, S-adenosylhomocysteine, cystathionine, cysteine, and sulfate are elevated, pointing to a remethylation or distal transsulfuration/oxidation block as the cause of hyperhomocysteinemia in renal failure. Stable isotope techniques have shown that both whole-body homocysteine remethylation and methionine transmethylation are decreased in renal failure, whereas homocysteine transsulfuration seems intact. Metabolic homocysteine clearance (i.e., transsulfuration relative to plasma homocysteine) is decreased to a major extent. These metabolic disturbances in renal failure can only be partially restored with current treatments. Folic acid treatment lowers plasma homocysteine concentration and increases remethylation and transmethylation rates. Plasma homocysteine, however, is not normalized, and metabolic homocysteine clearance by transsulfuration remains impaired. According to the currently available data, effective normalization of plasma homocysteine can only be obtained when its metabolic clearance through transsulfuration is restored.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
同型半胱氨酸和蛋氨酸在肾功能衰竭中的代谢。
肾功能不全总是伴随着含硫和潜在的血管毒性氨基酸同型半胱氨酸的血浆浓度升高。肾小球滤过率与血浆同型半胱氨酸浓度有密切关系。然而,与肌酐不同的是,同型半胱氨酸在肾小管中被迅速重吸收,其尿排泄很少。没有证据表明同型半胱氨酸会被人体肾脏主动清除。肾功能不全时,血浆s -腺苷蛋氨酸、s -腺苷同型半胱氨酸、半胱氨酸、半胱氨酸和硫酸盐浓度升高,提示再甲基化或远端转硫/氧化阻断是导致肾功能衰竭高同型半胱氨酸血症的原因。稳定同位素技术表明,在肾功能衰竭时,全身同型半胱氨酸再甲基化和蛋氨酸转甲基化都减少,而同型半胱氨酸转硫化似乎是完整的。代谢性同型半胱氨酸清除率(即相对于血浆同型半胱氨酸的转硫)在很大程度上降低。目前的治疗只能部分恢复肾功能衰竭的代谢紊乱。叶酸治疗降低血浆同型半胱氨酸浓度,增加再甲基化和转甲基化率。然而,血浆同型半胱氨酸不正常,代谢性同型半胱氨酸清除仍然受损。根据现有资料,血浆同型半胱氨酸的有效正常化只有在其经转硫代谢清除率恢复后才能实现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Prevention of stroke in patients with atrial fibrillation: Current strategies and future directions Dear readers Comparability of D-dimer assays in clinical samples. The role of qualitative D-dimer assays, clinical probability, and noninvasive imaging tests for the diagnosis of deep vein thrombosis and pulmonary embolism. Screening for deep vein thrombosis and pulmonary embolism in outpatients with suspected DVT or PE by the sequential use of clinical score: a sensitive quantitative D-dimer test and noninvasive diagnostic tools.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1